The Patient Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.
Stay Connected. Manage Your Care.
Access your health information anytime and anywhere, at home or on the go, with MyHealth.
- Message your clinic
- View your lab results
- Schedule your next appointment
- Pay your bill
The MyHealth mobile app from Stanford Health Care puts all your health information at your fingertips and makes managing your health care simple and quick.
Guest Services
24/7
We are available to assist you whenever you need it. Give us a call at 650-498-3333 or GuestServices@stanfordmed.org.
PHYSICIAN HELPLINE
Have a question? We're here to help!
Call 1-866-742-4811
Monday - Friday, 8 a.m. - 5 p.m.
REFER A PATIENT
Fax 650-320-9443
Track your patients' progress and communicate with Stanford providers conveniently and securely.
Philip Grant
Infectious disease doctor
Assistant Professor of Medicine (Infectious Diseases) at the Stanford University Medical Center
My research focuses on antiretroviral therapy and complications of HIV including immune reconstitution inflammatory disease, osteoporosis, and cardiovascular disease.
- 3351 El Camino Real
- Atherton, CA 94027
- Phone: 650-723-9001
Professional Overview
Professional Education
Residency: University of Washington Medical Center (2003) WA
Internship: University of Washington Medical Center (2001) WA
Medical Education: Univ of California San Francisco (2000) CA
Fellowship: Stanford University - Infectious Diseases (2010) CA
Fellowship: Stanford University - Infectious Diseases (2008) CA
Board Certification: Infectious Disease, American Board of Internal Medicine (2008)
Patient Ratings and Comments
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Publications
Encephalitis caused by chikungunya virus in a traveler from the kingdom of tonga.
Nelson, J., Waggoner, J. J., Sahoo, M. K., Grant, P. M., & Pinsky, B. A. (2014). Encephalitis caused by chikungunya virus in a traveler from the kingdom of tonga. Journal of clinical microbiology, 52(9), 3459-3461.
Association between Latent Proviral Characteristics and Immune Activation in Antiretrovirus-Treated Human Immunodeficiency Virus Type 1-Infected Adults.
Liang, E. C., Sceats, L., Bayless, N. L., Strauss-Albee, D. M., Kubo, J., & Blish, C. A. (2014). Association between Latent Proviral Characteristics and Immune Activation in Antiretrovirus-Treated Human Immunodeficiency Virus Type 1-Infected Adults. Journal of virology, 88(15), 8629-8639.
Clinical and Immunologic Predictors of Death After an Acute Opportunistic Infection: Results from ACTG A5164
Grant, P. M., Komarow, L., Sanchez, A., Sattler, F. R., Asmuth, D. M., & Zolopal, A. R. (2014). Clinical and Immunologic Predictors of Death After an Acute Opportunistic Infection: Results from ACTG A5164. HIV CLINICAL TRIALS, 15(4), 133-139.
Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa
Alistar, S. S., Grant, P. M., & Bendavid, E. (2014). Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC MEDICINE, 12.
Evolution of HIV treatment guidelines in high- and low-income countries: Converging recommendations
Richardson, E. T., Grant, P. M., & Zolopa, A. R. (2014). Evolution of HIV treatment guidelines in high- and low-income countries: Converging recommendations. ANTIVIRAL RESEARCH, 103, 88-93.
Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.
Alistar, S. S., Grant, P. M., & Bendavid, E. (2014). Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC medicine, 12, 46-?.
TREATING PSYCHOLOGICAL TRAUMA AMONG RWANDAN ORPHANS IS ASSOCIATED WITH A REDUCTION IN HIV RISK-TAKING BEHAVIORS: A PILOT STUDY
Talbot, A., Uwihoreye, C., Kamen, C., Grant, P., McGlynn, L., & Zolopa, A. (2013). TREATING PSYCHOLOGICAL TRAUMA AMONG RWANDAN ORPHANS IS ASSOCIATED WITH A REDUCTION IN HIV RISK-TAKING BEHAVIORS: A PILOT STUDY. AIDS EDUCATION AND PREVENTION, 25(6), 468-479.
Low Baseline CD4(+) Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation
Grant, P. M., Kitch, D., McComsey, G. A., Dube, M. P., Haubrich, R., & Brown, T. T. (2013). Low Baseline CD4(+) Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation. CLINICAL INFECTIOUS DISEASES, 57(10), 1483-1488.
Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202
Grant, P. M., Tierney, C., Budhathoki, C., Daar, E. S., Sax, P. E., & Katzenstein, D. (2013). Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202. HIV CLINICAL TRIALS, 14(6), 284-291.
Elevated Interleukin 8 and T-Helper 1 and T-Helper 17 Cytokine Levels Prior to Antiretroviral Therapy in Participants Who Developed Immune Reconstitution Inflammatory Syndrome During ACTG A5164
Grant, P. M., Komarow, L., Lederman, M. M., Pahwa, S., Zolopa, A. R., & Sereti, I. (2012). Elevated Interleukin 8 and T-Helper 1 and T-Helper 17 Cytokine Levels Prior to Antiretroviral Therapy in Participants Who Developed Immune Reconstitution Inflammatory Syndrome During ACTG A5164. JOURNAL OF INFECTIOUS DISEASES, 206(11), 1715-1723.
When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now!
Grant, P. M., & Zolopa, A. R. (2012). When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now!. Current HIV/AIDS reports, 9(3), 251-258.
Blood (1 -> 3)-beta-D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii Pneumonia
Sax, P. E., Komarow, L., Finkelman, M. A., Grant, P. M., Andersen, J., & Zolopa, A. R. (2011). Blood (1 -> 3)-beta-D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii Pneumonia. CLINICAL INFECTIOUS DISEASES, 53(2), 197-202.
Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis
Bendavid, E., Grant, P., Talbot, A., Owens, D. K., & Zolopa, A. (2011). Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS, 25(2), 211-220.
Concerns Regarding a Randomized Study of the Timing of Antiretroviral Therapy in Zimbabweans with AIDS and Acute Cryptococcal Meningitis
Grant, P. M., Aberg, J. A., & Zolopa, A. R. (2010). Concerns Regarding a Randomized Study of the Timing of Antiretroviral Therapy in Zimbabweans with AIDS and Acute Cryptococcal Meningitis. CLINICAL INFECTIOUS DISEASES, 51(8), 984-985.
Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164
Sax, P. E., Sloan, C. E., Schackman, B. R., Grant, P. M., Rong, J., & Freedberg, K. A. (2010). Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164. HIV CLINICAL TRIALS, 11(5), 248-259.
Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance
Grant, P. M., & Zolopa, A. R. (2010). Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 11(8), 901-910.
Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection
Grant, P. M., Komarow, L., Andersen, J., Sereti, I., Pahwa, S., & Zolopa, A. (2010). Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection. PLOS ONE, 5(7).
Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors
Talbot, A., Grant, P., Taylor, J., Baril, J.-G., Liu, T. F., & Zolopa, A. (2010). Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(6), 2473-2479.
International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase
Grant, P. M., Taylor, J., Nevins, A. B., Calvez, V., Marcelin, A.-G., & Zolopa, A. R. (2010). International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(4), 1520-1525.
Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life
Grant, P. M., Palmer, S., Bendavid, E., Talbot, A., Slamowitz, D. C., & Zolopa, A. R. (2009). Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life. JOURNAL OF CLINICAL VIROLOGY, 46(4), 305-308.
The use of resistance testing in the management of HIV-1-infected patients
Grant, P. M., & Zolopa, A. R. (2009). The use of resistance testing in the management of HIV-1-infected patients. CURRENT OPINION IN HIV AND AIDS, 4(6), 474-480.
Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose.
Grant, P., & Zolopa, A. (2009). Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose. Current HIV/AIDS reports, 6(2), 63-67.
Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor
Grant, P., Taylor, J., Cain, P., Short, W., Gallant, J., & Zolopa, A. (2009). Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor. CLINICAL INFECTIOUS DISEASES, 48(5), 680-682.
Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores
Grant, P., Wong, E. C., Rode, R., Shafer, R., De Luca, A., & Zolopa, A. (2008). Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(11), 4050-4056.
Integrase inhibitors: a clinical review of raltegravir and elvitegravir.
Grant, P., & Zolopa, A. (2008). Integrase inhibitors: a clinical review of raltegravir and elvitegravir. Journal of HIV therapy, 13(2), 36-39.
Patient Comments
3 Patient Comments
Patients comments are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
SHC Patient, Jul 2014
I drive 5 hours to see Dr. Grant. He and his staff are awesome.
SHC Patient, May 2014
The service and care was the best!
SHC Patient, Feb 2014
I really feel like I've won the lottery having such a wonderful dr. such as Dr. Grant. He is warm, attentive and helpful.